Telmisartan
Reading File
Finding Sources
Finding Sources
Searching PubMed
telmisartan
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I have sufficient information to deliver a thorough, well-structured answer on telmisartan. Here is the complete overview:
Telmisartan (Micardis)
Class & Chemical Structure
Telmisartan is an angiotensin II receptor blocker (ARB) - a nonpeptide, noncompetitive antagonist of the AT1 receptor. It belongs to the nonbiphenyl tetrazole subclass and incorporates a carboxylic acid as the biphenyl acidic group, distinguishing it structurally from losartan (which uses a tetrazole moiety). It has the longest elimination half-life among all ARBs (~24 hours), and its effects may persist up to 7 days after discontinuation.
(Brenner and Rector's The Kidney, 2-Volume Set)
Mechanism of Action
ARBs bind to AT1 receptors with high affinity and are >10,000-fold more selective for AT1 than AT2 receptors. Telmisartan inhibits the biological effects of angiotensin II at the AT1 receptor, including:
- Vascular smooth muscle contraction
- Rapid and slow pressor responses
- Thirst and vasopressin release
- Aldosterone secretion
- Adrenal catecholamine release
- Enhancement of noradrenergic neurotransmission
- Increases in sympathetic tone
- Changes in renal function
- Cellular hypertrophy and hyperplasia
Unlike ACE inhibitors, ARBs block AT1 receptors regardless of how AngII is formed (including via chymase and other ACE-independent pathways). They also permit activation of AT2 receptors - the increased circulating AngII caused by ARBs activates AT2 receptors, which may contribute to vasodilation and antiproliferative effects.
(Goodman & Gilman's The Pharmacological Basis of Therapeutics)
Unique Feature: PPAR-γ Partial Agonism
Telmisartan is the only ARB that also acts as a partial agonist at peroxisome proliferator-activated receptor gamma (PPAR-γ), similar to the thiazolidinedione class. This provides potential metabolic benefits including insulin sensitization and improvement in lipid profiles - making it particularly attractive in patients with hypertension plus metabolic syndrome or type 2 diabetes.
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Starting dose | 40 mg once daily |
| Usual dose range | 40-80 mg once daily |
| Time to peak plasma level | 0.5-1 hour |
| Elimination half-life | ~24 hours (longest among ARBs) |
| Duration of action | 24 hours; may last up to 7 days after stopping |
| Metabolism | <3% metabolized in liver to inactive compounds |
| Elimination | Primarily biliary secretion of intact drug |
| Renal effect on clearance | None - no dose adjustment needed in kidney disease |
| Hepatic effect on clearance | Reduced - use with caution in hepatic insufficiency |
| Dialyzable | No |
Sex difference: Women typically achieve plasma levels 2-3 times higher than men, though this is not associated with differences in blood pressure response.
(Brenner and Rector's The Kidney; Goodman & Gilman's)
ARBs vs. ACEIs - Key Differences
| Feature | ACEIs | ARBs (including telmisartan) |
|---|---|---|
| Blocks AngII formation | Yes (via ACE only) | No - blocks AT1 receptor regardless of how AngII is made |
| AT2 receptor | Not activated | Allows AT2 activation (potential benefit) |
| Bradykinin accumulation | Yes (causes cough/angioedema) | No |
| Cough | 5-20% of patients | Absent |
| Angioedema | 0.1-0.5% | Rare (much less than ACEI) |
Indications
- Hypertension - first-line treatment, especially in patients with:
- Diabetes mellitus / metabolic syndrome (PPAR-γ benefit)
- Chronic kidney disease with proteinuria
- Intolerance to ACE inhibitors (cough/angioedema)
- Cardiovascular risk reduction - studied in the landmark ONTARGET trial (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial): telmisartan 80 mg was non-inferior to ramipril 10 mg in reducing the composite of cardiovascular death, MI, stroke, and hospitalization for heart failure in high-risk patients. Combination of the two was not superior and caused more adverse effects.
- Antipsychotic-associated hypertension - specific evidence supports telmisartan and valsartan for this indication (Maudsley Prescribing Guidelines in Psychiatry)
Adverse Effects
Telmisartan and ARBs as a class are generally well-tolerated. Important adverse effects include:
- Hyperkalemia - especially in renal insufficiency, diabetes, or when combined with K+-sparing diuretics, K+ supplements, or NSAIDs
- Hypotension - particularly first-dose or in volume-depleted patients
- Acute renal failure - possible in bilateral renal artery stenosis, single-kidney stenosis, or severe heart failure (same mechanism as ACEIs)
- Fetopathic effects - associated with renal developmental defects when used in pregnancy (especially 2nd/3rd trimester); contraindicated in pregnancy
- Cough and angioedema are significantly less common than with ACEIs
- Diarrhea, upper respiratory infections (mild)
Contraindications
- Pregnancy (absolute)
- Bilateral renal artery stenosis (relative)
- Concurrent use with aliskiren in patients with diabetes or eGFR <60 mL/min
- Do not combine with ACEIs (dual RAS blockade increases harm without additional benefit - shown in ONTARGET)
Drug Interactions
- K+-sparing diuretics / K+ supplements → hyperkalemia
- NSAIDs → reduced antihypertensive effect, worsened renal function
- Lithium → increased lithium levels (monitor)
- Digoxin → telmisartan can increase digoxin levels (monitor)
- Other antihypertensives → additive BP lowering
Position Among ARBs
Compared to other ARBs, telmisartan has:
- The longest half-life (~24 h, vs. losartan ~2.5 h, valsartan ~9 h)
- The only PPAR-γ agonist activity in the class
- No renal dose adjustment needed
- Mainly hepatic/biliary clearance (unlike losartan which has both hepatic and renal)
- Well-suited for once-daily dosing with excellent 24-hour BP coverage
A 2024 network meta-analysis (Zhang et al., Int J Clin Pharm 2024) comparing six ARBs found telmisartan to be among the most effective for BP reduction, consistent with its high receptor affinity and long duration of action.
Sources: Brenner and Rector's The Kidney, Goodman & Gilman's The Pharmacological Basis of Therapeutics, Lippincott Illustrated Reviews: Pharmacology, The Maudsley Prescribing Guidelines in Psychiatry, 15th ed.
This is a shared conversation. Sign in to Orris to start your own chat.